title: A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB.
abstract: Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients' tolerance, compliance and treatment completion.
authors.affiliation: Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.
authors.forename: J L
authors.initials: JL
authors.lastname: Potter
authors.affiliation: Department of Medicines Management and Pharmacy Services, Leeds University Hospitals Trust, Leeds, UK.
authors.forename: T
authors.initials: T
authors.lastname: Capstick
authors.affiliation: Department of Respiratory Medicine, The Whittington Hospital, London, UK.
authors.forename: W M
authors.initials: WM
authors.lastname: Ricketts
authors.affiliation: Department of Respiratory Medicine, Queen Alexandra Hospital, Portsmouth, UK.
authors.forename: N
authors.initials: N
authors.lastname: Whitehead
authors.affiliation: Imperial College London, Chest and Allergy Clinic, London, UK.
authors.forename: O M
authors.initials: OM
authors.lastname: Kon
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D006113:United Kingdom
chemical_list: D000995:Antitubercular Agents
keywords: Drug reactions; Respiratory Infection; Tuberculosis